Navigation Links
Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
Date:4/30/2009

of capital converted, and the consolidation of its common shares on a 10 for 1 basis. The transfer of the assets of the Neurobionix division will also be implemented by way of the plan of arrangement.

Victhom expects to hold separate debenture holder and shareholder meetings in early June to obtain certain required approvals for the above-mentioned plan of arrangement as well as the creation of the JV. Further details on the plan of arrangement and the transaction with Otto Bock will be provided in an information management circular expected to be distributed to its shareholders and debenture holders by mid-May. In addition to debenture holders and shareholders approvals, implementation of the JV transaction and the plan of arrangement is subject to approval by the Court under the Canada Business Corporations Act and receipt of all necessary regulatory and stock exchange approvals.

The principal debenture holders and shareholders have executed support agreements with Victhom and Otto Bock whereby they agreed to vote in favor of the transaction with Otto Bock and the concurrent implementation of the plan of arrangement.

The board of directors of Victhom is recommending to both the shareholders and the debenture holders to support the transaction as it will provide Victhom with the opportunity to develop its technologies under new parameters providing a stronger financial base for the future.

Mr. Normand Rivard, Acting President and CFO of Victhom, said: "We are tremendously enthusiastic with the prospect of teaming up with Otto Bock, the world leader in the field of mobility. This partnership is designed to exploit the great potential of our unique Neurobionix technology platform incorporated in the Neurostep. The combination of our technology know-how and Otto Bock's worldwide market knowledge will give us a tremendous edge in bringing this much needed solution to gait patients throughout the world. The interest from Otto Bock is a v
'/>"/>

SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)
2. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
3. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
4. Victhom announces the completion of the second phase of the apnea therapy development
5. Victhom Announces Launch of Enhanced Company Website
6. Victhom to Participate in the OneMedPlace Finance Forum
7. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
8. DATATRAK International, Inc. Forms Strategic Partnership with Inclinix, Inc.
9. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
10. E&K Scientific Announces Partnership with Sciformatix
11. PRA International Presents Key Budgeting Strategies at 18th Annual CRO Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... , ... August 26, 2015 , ... PRC Clinical, ... develop new business relationships with local sponsors in southern California. The Clinical Trial Management ... drug development processes and regulatory pathways., , Stem Cell ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Multiple Ultrasound Solution Provider Doubles Sales Over Same Period Last ... ... WAUKESHA, Wis., Aug. 27 MedPro Imaging, a premier,provider of ... representing a doubling of sales,over the same period last year. Recent ...
... Following the successful acquisition of,Drug Development Solutions (,DDS,) ... today that it has fully,integrated its two early ... Early Phase., Chiltern Early Phase is providing ... via its two well established units in Slough,(just ...
... Inc. (Nasdaq: AMLN ) and Eli Lilly and ... provided context and additional information,regarding the August 18, 2008 ... alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The companies were ... well as others, and previously reported these cases to ...
Cached Biology Technology:MedPro Installs 1000th Ultrasound System Worldwide 2Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... cancer as a major cause of death among children ... adequately addressed by national or international health organizations and ... Hospital. This growing rate of pediatric cancer is occurring ... is being reduced through the efforts of the World ...
... prices at the gas pump could come in the ... biomass, according to a joint feasibility study for the ... Oak Ridge National Laboratory report outlines a national strategy ... organic matter that is available on a renewable or ...
... everything was big has helped Queensland researchers to unearth ... responsible for wiping out Australian giant marsupials or megafauna ... specimens' such as giant kangaroos and wombats, the researchers ... performed the first systematic analysis of a site in ...
Cached Biology News:Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3Human Cells Filmed Instantly Messaging for First Time 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: